ONYX-015 is an attenuated chimeric human group C adenovirus, which preferentially replicates in and lyses tumor cells that are p53 negative. The purpose of this phase I, dose-escalation study was to determine the safety and feasibility of intravenous infusion with ONYX-015 in combination with enbrel in patients with advanced carcinoma. Enbrel is a recombinant dimer of human tumornecrosis factor (TNF)-a receptor, previously shown to reduce the level of functional TNF. Nine patients, three in each cohort received multiple cycles of ONYX-015 infusion (1 Â 10 10 , 1 Â 10 11 and 1 Â 10 12 vp weekly for 4 weeks/cycle) in addition to subcutaneous enbrel (only during cycle 1) injections per FDA-indicated dosing. Of the nine patients, four had stable disease. No significant adverse events were attributed to the experimental regimen, confirming that enbrel can be safely administered along with oncolytic virotherapy. Two of the three patients in cohort 3 had detectable viral DNA at days 3 and 8 post-ONYX-015 infusion. Their detectable circulating viral DNA was markedly higher during cycle 1 (with enbrel coadministration) as compared with cycle 2 (without enbrel) at the same time points. Area under the curve determinations indicate a marked higher level of TNF-a induction and accelerated clearance at cycle 2 in the absence of enbrel. Further assessment is recommended.
Introduction
ONYX-015 is an attenuated chimeric human group C adenovirus (Ad2 and Ad5) engineered with a deletion of the E1B55 kDa gene to replicate selectively in and lyse tumor cells with deficient and/or dysfunctional p53 tumor suppressor gene activity. Recent data suggest that the elimination of E1B55 kDa-mediated late viral RNA export is more likely the mechanism of replicative selectivity in target cells. 1 Previously, i.v. infusions of ONYX-015 at doses up to 2 Â 10 13 particles alone, or in conjunction with chemotherapy, have successfully demonstrated the safety and feasibility of systemic ONYX-015 administration, 2, 3 but with limited clinical effectiveness. A possible explanation for this lack of effectiveness is an accelerated viral clearance mediated by the patient's immune response.
A marked elevation of the serum cytokine tumornecrosis factor (TNF)-a has been commonly observed in patients following ONYX-015 infusion. 2, 3 The increase in this proinflammatory cytokine level has been shown to contribute to viral clearance through the induction of adhesion molecules and the production of viral-neutralizing antibodies. In TNF knockout mice 4 and in mice receiving adenoviral vectors expressing chimeric fusion TNFR-CD8 to inhibit TNF ligand, 5 adenoviral survival and adenoviral transgene expression were extended concomitantly.
Enbrel (etanercept), a recently FDA-approved anti-TNF therapeutic, is a synthetic dimer of the 75 kDa (p75 kDa) TNF receptor (TNFR) linked to the F C portion of human IgG1. Enbrel has a 50-fold greater affinity for [ 125 I]human recombinant TNF-a ( 125 I-hrTNF-a) in a binding inhibition assay and is 1000-fold more efficient in an in vitro cytoprotection assay than monomeric soluble TNFR. Multiple clinical trials have demonstrated the success of this competitive inhibitor of TNF-a binding to its cognate receptor in ameliorating diseases, in which chronic inflammation plays a pathophysiologic role, including Crohn's disease, juvenile arthritis, adult rheumatoid arthritis and psoriatic diseases. [6] [7] [8] Treatment with enbrel results in reduction in multiple proinflammatory cytokines and adhesion molecules, decreases cell trafficking and angiogenesis, and halts joint destruction. 6 The E1B-19K and E3B viral genes encoded by the wild-type adenovirus are functionally redundant with respect to their capacity to antagonize TNF-a induction, thereby contributing to enhanced viral replication and spread. E3B deletion, as found in ONYX-015, has been shown to accelerate immune-mediated viral clearance in vivo. 9 We hypothesize that the use of adjunctive enbrel, which has been shown to reduce the level of functional TNF and other consequent cytokines, will downregulate TNF-induced activation events that contribute to viral clearance. To this end, we initiated a phase I, viral dose-escalation trial to determine safety and feasibility of combined treatments with enbrel and intravenously infused ONYX-015.
Methods

Test article
ONYX-015 is a chimeric human group C adenovirus (Ad2 and Ad5) that does not express the 55 kDa product of the E1B gene. The virus contains a deletion between nucleotides 1496 and 3323 in the E1B region encoding the 55 kDa protein. In addition, a C to T transition at position 2022 in E1B generates a stop codon at the third codon position of the protein. These alterations eliminate expression of the E1B 55 kDa gene in ONYX-015-infected cells. ONYX-015 was manufactured using the human embryonic kidney cell line HEK293, and supplied and frozen (À201C) in 0.5 ml vials. The viral particle (vp) to PFU ratio was 72. Wild-type adenovirus was undetectable in all clinical lots of ONYX-015 at a limit of detection of 1 in 10 11 particles.
Study design
This was an open-label, single site phase I, dose escalation of ONYX-015 to determine safety of this virus in combination with enbrel. Patients received ONYX-015 treatment on days 1, 8 and 15 of a 3-week cycle. Three cohorts of patients were studied with viral dose levels of ONYX-015 ranging from 1 Â 10 10 (cohort 1), 1 Â 10
11
(cohort 2) to 1 Â 10 12 (cohort 3) viral particles per injection. Enbrel was administered at the FDA-indicated dose of 25 mg subcutaneously, twice a week at 72-96 h apart before cycle 1 (À1 week, days 1 and 4), then throughout cycle 1 (days 1 and 4, 8 and 11, and 15 and 18) in conjunction with ONYX-015 administration for cycle 1 only. Patients then received a second cycle of ONYX-015 at the same dose without enbrel. Those who completed cycle 2 with clinical evidence of tumor and/or roentgenographic disease stabilization with no documented doselimiting toxicity (DLT) were permitted to continue with ONYX-015 alone at the same dose level in subsequent cycles.
ONYX-015 preparation and intravenous infusion ONYX-015 was formulated as a sterile viral solution in TRIS buffer. The 0.5 ml solution, provided frozen in single-use, plastic screw-cap vials was thawed and maintained at 2-81C during dilution and handling, and administered to patients within 2 h from viral preparation. Appropriate volumes of the viral stock were diluted to 10 ml with normal saline. A single injection of 10 ml was administered over approximately 3-5 min as specified in the product information sheet through a peripheral or central i.v. line (X22-gauge catheter).
Study population
Patients were treated at the Mary Crowley Medical Research Center located in the Sammons Cancer Center at Baylor University Medical Center in Dallas, TX, USA. Adult patients with advanced cancer who had failed at least one prior therapeutic regimen and for whom effective conventional therapy was not available were eligible for the study. All patients were required to have histologically or cytologically confirmed carcinoma with Karnofsky performance status of 490%, life expectancy of X3 months, absolute neutrophils 41500/ml, hemoglobin 49 mg/dl, platelets 475 000/ml, creatinine o2.0 mg/dl, AST and ALT42-fold upper limit of normal, international normalized ratio (INR)p2.0, partial thromboplastin time (PTT) within normal limits and total bilirubin o3.0 mg/dl. All patients consented to study participation on an Institutional Review Board (IRB)-approved consent form. Women and men of reproductive potential were required to use a reliable form of contraception.
Patients with the following conditions were excluded from the study: those with 450% liver replacement by tumor as determined radiographically; ongoing active infection (including human immunodeficiency virus but excluding asymptomatic bacterial colonization); viral syndrome diagnosed within the last 2 weeks; chemotherapy within the last 3 weeks (6 weeks for nitrosourea or mitomycin-C); radiotherapy to tumor site within the last 4 weeks (if this is the only site of disease); concomitant hematological malignancy (that is, chronic lymphocytic leukemia or non-Hodgkin's lymphoma); active rheumatoid arthritis; an ongoing requirement for chronic immunosuppressive mediation such as glucocorticoid or cyclosporin, or chronic use of any such medicine within the past 4 weeks. Pregnant or lactating women were excluded in addition to those who had previously participated in research protocols involving administration of adenovirus vectors. Furthermore, patients with prior treatment with etanercept or infliximab and those with active seizures requiring anticonvulsants were excluded.
Tumor-response assessment Up to five masses were measured for response assessment. A complete response was defined as a complete disappearance (CD) of all tumors at the assessed site. A partial response (PR) was defined as a regression of the product of the cross-sectional diameters of the tumor mass by X50% but o100% with no growth of any individual lesion. Stable disease (SD) was defined as a tumor mass decrease by o50% or increase in size by o25% for a minimum of 2 months. Progressive disease (PD) was defined as X25% increase in tumor size. Tumor response was evaluated by computed tomography (CT) scans before every other cycle.
Adverse event definition
The severity grade of adverse events was assigned according to the NCIC-CTC Expanded Common Toxicity Criteria. A grade 1, or mild, toxicity was defined as a noticeable event that did not interfere with normal daily activities. A grade 2, or moderate, toxicity was defined as an event sufficient enough to interfere with normal daily activities. A grade 3, or severe toxicity was defined as an incapacitating event leading to the inability to perform daily activities, and possibly requiring hospitalization. A grade 4 or life-threatening toxicity, was defined as an event possessing immediate risk of death at occurrence, and grade 5 events were defined as fatal.
Screening and pretreatment evaluation
Before treatment with ONYX-015, CT scans, chest radiographs and/or ultrasound evaluations were completed. Screening and pretreatment included a CT scan or ultrasound of the liver/abdomen with tumor measurements as well as a CT scan of known suspected disease sites; tumor markers (if applicable), a chest X-ray (PA/ lateral); a 12-lead electrocardiogram (ECG); complete medical history including secondary diagnosis, complete physical examination, baseline medical events and medications within the last 2 months. Screening and pretreatment also included an assessment of Karnofsky performance score; hematological tests including prothrombin time (PT) and INR and PTT; serum chemistry tests; neutralizing antibodies to ONYX-015; ONYX-015 in plasma; urinalysis; urine or serum pregnancy test; paraffin tumor block; and cellular immune assessment.
Treatment evaluation on days 1, 8 and 15
Vital sign assessments were taken at baseline (45 min before ONYX-015 infusion 715 min), then repeated immediately before infusion and at the conclusion of the infusion at the 15 min mark twice, then every 30 min thereafter for a total of 120 min. Subsequent cycles were continued as long as progressive disease was not observed and the patient was not removed due to unacceptable toxicity.
Procedures during the ONYX-015-treatment period Day 1 (71 day) evaluation involved a brief physical examination directed to relevant signs, symptoms, vital signs and weight. Blood for hematological tests and serum chemistry tests (including liver function) were also collected on this day. For day 1 of every other cycle beginning with cycle 3, cellular immune count was performed. Enbrel was administered through cycle 1 only. For all patients in treatment cycles 1, 2 and 3, cytokine analysis was performed at baseline, 671, 2473, 4873, 7273, 9673 and 16873 h post injection. On days 3 and 5, serum liver tests were performed. On cycle 1, day 3, plasma for PCR was collected. On days 8 and 15 of cycle 1, archival plasma samples, neutralizing antibodies for group C adenovirus (ONYX-015), and plasma for PCR were all collected. On days 8 and 15 of each cycle, hematological tests, serum chemistry tests including liver function, a physical examination and reporting of adverse events were all performed.
Pharmacokinetic venous blood draws
All patients had pharmacokinetic blood draws taken on days 1, 8 and 15 of cycle 1. Blood was drawn at the beginning of ONYX-015 infusion and at 5, 10, 30, 60, 90, 120, 180 and 360 min. Pharmacokinetics were taken on day 1 of cycle 2 only at time 0 before ONYX-015 infusion and at 30, 90, 120 and 360 min.
Off study assessment
Patients who complete their final cycle of ONYX-015 treatment or who were taken off treatment for other reasons were assessed as follows: physical examination, determination of Karnofsky performance status, hematology and chemistry, urinalysis, documentation of adverse events, documentation of concomitant medications and analysis of tumor response and tumor markers (if applicable).
Statistical analysis
This study contained three treatment cohorts containing a total of nine patients. The data for each cohort were summarized with descriptive statistics, frequency tabulations, graphs and data listings as appropriate. Two-tailed paired and t-test analysis were performed between cycles 1 and 2 (statistics Guide, Graph Pad Prism Software version 4.0, San Diego, CA)
Quantitative PCR of ONYX-015 genome A TaqMan-based real-time PCR assay to quantify specifically ONYX-015 DNA was used, as described previously by us and others, 10, 11 with further modifications. Real-time PCRs were carried out for the quantification of a 92-nt sequence from nt2452 to nt2544 of the ONYX-015 virus, which overlaps the deleted E1B region and includes an 8-bp Puc-derived linker insert. The central region of the probe is homologous to the liner insert, making the probe specific for ONYX-015 and eliminates detection of wild-type adenovirus sequences. The primers and probe specific to ONYX-015 virus (Sigma/Proligo, St Louis, MO, USA): forward primer, GCTGGCGCAGAAGTATTCCA; reverse primer, GTGCGGGTCTCATCGTACCT; probe: 6-Fam-AC CTTCCAGATCCGTCGACCTGCA-Tamra. 10 A standard curve was prepared with serially diluted ONYX-015 virus (2 Â 10 8 -2 Â 10 2 vp/ml) in normal human serum AB (Gemini Bio-Products, West Sacramento, CA, USA). Viral DNA was extracted by adding 3 mg of carrier DNA (polydeoxyadenylic acid; Sigma) into 0.5 ml of patient samples, standards and controls with known viruses, using the QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). The viral DNA was eluted in 100 ml nuclease-free water. Ten microliters of each elutant (10 ml) was analyzed in duplicates with Applied Biosystem Core reagents used in PCR, using the iCycler real time thermal cycler (BioRad, Hercules, CA, USA). The lower limit of quantification is 2 Â 10 3 particles of ONYX-015 per milliliter of plasma, and the lower limit of detection is 2 Â 10 2 particles/ml.
Cytokine analysis
An enzyme-linked immunosorbent assay (ELISA; R&D Quantikine Kit, Minneapolis, MN) was used for the quantification of serum circulating TNF-a level at defined treatment time points, days 1 to 5 and 8 of each cycle. Briefly, peripheral blood from the patient is collected by venipuncture, and serum samples extracted after clotting is stored at À201C. Serial serum samples from the same patient were analyzed simultaneously, using cytokinespecific immunoassay reagents according to the manufacturer's protocols. The colorimetric reaction was quantified as a function of optical density (OD) absorbance at 540 nm (SpectraMax 340; Molecular Devices, Sunnyvale, CA, USA). Cytokine concentration was calculated according to a reference standard curve and OD values of known, graded concentrations of the recombinant cytokine. The minimal detectable concentrations of TNF-a is o4 ng/ml, as defined by OD reading at greater than or equal to threefold higher than background. On the basis of inter-and intrasample variations, increases in cytokine level of X50% over baseline were considered significant.
Determination of ONYX-015-neutralizing antibody titers
Serum adenovirus-neutralizing antibody (NAb) titer was determined as function of the capacity to block ONYX-015 infectivity to viral permissive HEK293 cells. 10, 12 Patient serum samples were heat inactivated (561C, 30 min). Serially diluted serum samples in fresh culture medium (1:4-1:65 536 in twofold increments) were incubated with 10 5 ONYX-015 viral particles (1 h, 371C) in a humidified incubator (5% CO 2 , 95% air), together with the positive control of ONYX-015 with no test serum treatment. The reactants were transferred to 96-well flatbottom plate wells in triplicate, to which subconfluent 293 cells were added to attain a multiplicity of infection of 10 vp/cell (100 ml; 3 Â 10 5 cells/ml). Control wells included 293 cells alone with no virus (no cytopathic effect), 293 cells þ ONYX-015 without test sera (positive control; complete cytopathic effect) and 293 cells þ ONYX-015 þ reference serum samples with predetermined (NAb) titer. The culture was examined microscopically for cytopathic effect every 24 h up to 96 h. The reactions were evaluated when untreated 293 cells reached 80-100% confluence, and when 293 cells þ ONYX-015 cultures displayed complete lysis of the cell monolayer. The presence of NAb titer was graded microscopically as: 'À' if cytopathic effects, including rounding up and detachment, persist in X40% cells in the well; or ' þ ' (protective), when o40% of the cells were intact and remained attached as monolayer. NAb titer was determined in reference to the highest serum dilution that offered protection from viral cytopathic effects.
The analyses of serum viral load, cytokine and neutralizing antibodies were performed in a blinded fashion.
Results
Patient profile
The age, sex, Karnofsky performance status, site of disease, histologic tumor type, prior treatments and p53 status of the nine treated patients are shown in Table 1 . These nine patients received a total of 79 infusions of ONYX-015.
Adverse events
Few grade 3 or 4 toxic events were experienced by patients. No grade 3 or greater adverse events were attributable to the experimental therapeutic regimen. The most common of these unrelated toxicities was hyponatremia ( Table 2 ). All patients developed transient grade 1 or grade 2 fever with 24 h of ONYX-015 infusion.
Viral Kinetics
Real-time PCR analysis revealed detectable levels of circulating ONYX-015 at 72 h postviral infusion in patients who received 1 Â 10 11 (cohorts 2, 3/3) or 1 Â 10 12 vp (cohort 3, 2/3; Table 3a ). Pharmacokinetic evaluation of a cohort of three patients to determine viral DNA at 5-360 min post infusion indicated a similar viral clearance rate during cycle 1 (with enbrel) and cycle 2 (without enbrel; data not shown). Patients 1909 and 1910 demonstrated detectable circulating viral DNA at days 3 and 8 post infusion at cycle 1. It is of interest to note that both patients displayed a higher circulating viral content in cycle 1 (with enbrel) than cycle 2 (without enbrel; patient 1909: 5.8 Â 10 8 vp/ml at cycle 1 vs 0 vp/ml at cycle 2 on day 3; 4.5 Â 10 3 vs 7.2 Â 10 2 vp/ml at day 8; patient 1910: 2.4 Â 10 3 vp/ml at cycle 1 vs 1.2 Â 10 2 vp/ml at cycle 2 on day 3; 7.5 Â 10 5 vs 1.3 Â 10 3 vp/ml at day 8).
Neutralizing antibody response
All patients exhibited an increase in NAb titer over time, following ONYX-015 infusion. The median increase was 128-fold for cohort 1, 512-fold for cohort 2 and 1024-fold for cohort 3 at day 15 postviral infusion. Preexisting NAbs (median titer of 1:512) were detected in two of the three patients who received 1 Â 10 10 vp (cohort 1). None of the three cohort 1 patients demonstrated detectable circulating virus at day 8, including 1904 who had low preexisting NAb titer (Table 3b) 
Effect of enbrel on serum TNF level
To validate the biologic outcome of enbrel treatment, a TNF-specific ELISA was carried out to determine patient serum TNF level over the course of treatment. For comparison, the arbitrary standard of a doubling of previral infusion level was considered a clinically significant immunoreactive TNF response. By this criterion, one of the three cohort 1 patients, three of the three cohort 2 patients and two of the three cohort 3 patients displayed elevated TNF responses at days 2-5, cycle 1 with enbrel coadministration (Figure 1 ). Data also demonstrate a statistically significant increase in immunoreactive TNF at cycle 2 day 1 as compared with cycle 1 day 1 within each dose level and for all cohorts (1368.2 vs 477.7 pg/ml at 24 h; P ¼ 0.0076). Statistically significant lower levels of serum immunoreactive TNF-a were seen on days 4 and 5 without enbrel (cycle 2; P ¼ 0.0009 and 0.0066, respectively; Figure 1 ) as compared with the same time points at cycle 1 with enbrel. Peak response for all cohorts in cycle 2 occurred at day 1 postviral infusion and was also significantly higher than that observed at day 2 in cycle 1 with enbrel (Table 4 ; Po0.05). Area under the curve calculations indicated that TNF-a clearance was accelerated at cycle 2 for all cohorts (Table 4) . These findings were consistent with a marked higher TNF-a induction and clearance at cycle 2 in the absence of enbrel.
Treatment response
Time to progression of disease as well as survival are also shown in Table 5 .
Discussion
Despite the favorable responses following local/regional administration, oncolytic adenoviruses have had limited efficacy as stand-alone systemically administered agents. In our previously completed pilot study, single infusion or weekly infusions of ONYX-015 were administered intravenously to 20 advanced cancer patients. 11, 13 No doselimiting toxicities were identified; mild-to-moderate fever, rigors and mild transient transaminitis (following high doses only) were the most common side effects. This lack of significant toxicity is remarkable given the evidence for ongoing viral replication and shedding into the circulation for several weeks in high-dose patients. Toxicity was not altered when ONYX-015 was administered with chemotherapy (CPT11, 5FU, taxol and carboplatin) or IL-2. However, no firm response was demonstrated in any patients.
There are a number of mechanisms, either individually or in combination, that could account for the limited systemic effectiveness of oncolytic adenoviral therapy despite the responses seen with intratumoral and regional therapy. 2, 14 These include (1) rapid viral uptake and clearance by hepatocytes (via the coxsackie-adenoviral receptors or heparin sulfate glycosaminoglycans 15 ) and/or Abbreviations: F, female; M, male; NSCLC, non-small cell lung cancer; XRT, X-ray therapy.
Intravenous infusion of ONYX-015 and enbrel in solid tumor J Nemunaitis et al red blood cells, 16 which limit malignant cell exposure to the virus; (2) cytokine induction, particularly TNF-a and interferon-g (IFN-g), which leads to innate immune activation that reduces viral survival; and (3) neutralizing antibody elevation as a derivative adaptive immune mechanism that further lowers viral half-life. The marked elevation of circulating IL-6, IL-10, IFN-g and TNF-a that we observed following i.v. ONYX-015 infusion supports the premise of an antiviral immune response that accelerated viral clearance. 2, 17 The pivotal role of TNF has been demonstrated in multiple animal studies, where deficiency or inhibition of TNF increased adenoviral half-life and therapeutic effectiveness.
Recently, a number of clinical trials have been initiated in cancer patients to examine safety and efficacy of enbrel as monotherapy 18, 19 or as adjunct to chemotherapy. 20 The addition of enbrel was safe, and appeared to improve tolerability of dose-intensive chemotherapy by relieving fatigue in advanced cancer patients. 20 Other than a small increase in severe infections, enbrel generally displayed an excellent safety profile. Although patients with rheumatoid arthritis are at an increased risk for lymphoma, in studies of three different cohorts of patients there was no evidence of increased risk of lymphomas in the TNFagonist-treated group. 21 To define safety and, secondly, efficacy of combined treatment with ONYX-015 and enbrel, our study involved the administration of enbrel for 4 weeks (starting week À1), without chemotherapy to limit the number of variables potentially affecting the immune response. Although a number of grade 3 and one grade 4 toxic events were observed, none were attributable to enbrel. These findings confirm that enbrel plus ONYX-015 infusion is safe at the doses tested, further reinforcing previous findings that up to 2 Â 10 13 particles of ONYX-015 can be safely administered alone, or in combination with chemotherapy or IL-2 with limited side effects. Abbreviation: vp, viral particle. Abbreviations: Ab, antibody; vp, viral particle.
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However, the observed levels of TNF production following viral treatment (o2000 pg/ml) are several orders of magnitude below the minimum effective dose (mg amounts) needed to achieve these antitumor effects. 22 Hence, it is unlikely that enbrel coadministration would negate potential antitumor effects resulting from TNF production. Animal studies support a central role for TNF-a in the clearance of viral particles. TNF-a gene knockout mice Abbreviations: AUC, area under curve for Figure 1 , and was determined by Graph Pad prism software analysis (Prism, see Methods section); TNF-a, tumor-necrosis factor-a.
a Calculated by the formula: Peak response/AUC. b Differed significantly from cycle 1 (po0.05) based on two-tailed, paired t-test analysis.
have prolonged the presence of nonreplicating adenoviral vectors. 4 Vector-delivered transgene expression was similarly prolonged in TNF-a-depleted mice, as well as in mice treated with a chimeric fusion TNFR-CD8 TNF-a inhibitor. 5, 23 For patients who received enbrel pretreatment followed by infusion of X1 Â 10 11 vp (cohorts 2 and 3), 1 Â 10 3 -6 Â 10 5 circulating viral particles were detected in three of the three patients at 72 h postviral infusion. By comparison, only two of the seven patients who received a comparable dose of ONYX-015 (without enbrel pretreatment) displayed measurable levels of virus at 48 h post infusion in our previously conducted trial. 3 Further, both cohort 3 patients with detectable, circulating viral DNA at days 3 and 8 displayed a higher viral titer in cycle 1 when enbrel was coadministered. Each of the two patients demonstrated similar viral pharmacokinetics during the initial phases of cycles 1 and 2 (5-360 min post infusion). These findings suggest that the presence of NAbs may not be the predominant determinant for the differential viral titer at later phases of cycles 1 and 2.
These limited findings suggest that enbrel coadministration may reduce the clearance of i.v. administered ONYX-015. A biologic effect of enbrel may be inferred by quantitative differences in the patients' serum immunoreactive TNF-a levels in cycle 1 as compared with cycle 2. Enbrel coadministration in cycle 1 produced a modest increase at 24 h for cohorts 1-3, as compared to an accelerated and significantly higher increase in cycle 2. At later time points of 48 h post-ONYX-015 infusion and thereafter, the mean levels of immunoreactive TNF for all cohorts were higher at X48 h than those in cycle 2, reaching statistical significance on days 4 (524.7 vs 252.2 pg/ml, P ¼ 0.009) and 5 (577.8 vs 210.3 ng/ml, P ¼ 0.0066). Previous studies have consistently shown a delayed increase in immunoreactive serum TNF-a levels following enbrel administration in cancer patients in conjunction with negative TNF-a biologic activity. 18, 19 An accelerated TNF-a induction and clearance in cycle 2 for all cohorts is suggestive of an enbrel-mediated outcome in cycle 1. The induction of antiviral immune responses likely contributes to increased clearance, particularly at cycle 2. Nonetheless, our findings support the premise that enbrel pre-and coadministration during cycle 1 contributed to a reduction of biologically effective TNF-a responses against viral administration, but far from completely eliminating circulating TNF-a. The measurement of biofunctional TNF is warranted. However, currently available assays for measuring TNF biofunction in human serum is both lacking in specificity and sensitivity. 24 The half-life of enbrel is 102730 h. A more intense enbrel dosing schedule may conceivably reduce further TNF-a activity. Intravenous infusion of ONYX-015 and enbrel in solid tumor J Nemunaitis et al
